Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir

AIDS

Volumn 25, Issue 13, 2011, Pages 1603-1609

  Brennan, Alana ^a,b,c   Evans, Denise ^b,e   Maskew, Mhairi ^b,e   Naicker, Saraladevi ^c   Ive, Prudence ^e   Sanne, Ian ^d,e   Maotoe, Thapelo ^d   Fox, Matthew ^a,b,c  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^b Health Economics and Epidemiology Research Office   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d RIGHT TO CARE   (South Africa)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

creatinine clearance; lost to follow up; mortality; nephrotoxicity; resource limited setting; tenofovir

Indexed keywords

TENOFOVIR;

AFRICA; ARTICLE; CREATININE CLEARANCE; DISEASE ASSOCIATION; DRUG FATALITY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEPHROTOXICITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR;

ADENINE; ADULT; ANTI-HIV AGENTS; COHORT STUDIES; CREATININE; FEMALE; HIV INFECTIONS; HUMANS; KIDNEY; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; RENAL INSUFFICIENCY; RISK FACTORS; SOUTH AFRICA;

EID: 80051798090     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834957da     Document Type: Article

References (43)

1. Pollak MR. Kidney disease and African ancestry. Nat Genet 2008;40:1145-1146.
2. Naicker S. End-stage renal disease in sub-Saharan Africa. Ethn Dis 2009;19(Suppl 1):S1-5-S13-5.
3. Reid A, Stöhr W, Walker AS, Williams IG, Kityo C, Hughes P, et al. Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. Clin Infect Dis 2008;46:1271-1281. (Pubitemid 351589914)
4. Gallant JE, Parich MA, Keruly JC, Moore RD. Changes in renal function associated with Tenofovir Disoproxil Fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005;40:1194-1198. (Pubitemid 40490248)
5. Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 2006;42:283-290. (Pubitemid 43054205)
6. Woodward CL, Hall AM, Williams IG, Madge S, Copas A, Nair D, et al. Tenofovir-associated renal and bone toxicity. HIV Med 2009;10:482-487.
7. Schmid S, Opravil M, Moddel M, Huber M, Pfammatter R, Keusch G, et al. Acute interstitial nephritis of HIV-positive patients under atazanavir and tenofovir therapy in a retrospective analysis of kidney biopsies. Virchows Arch 2007;450:665-670. (Pubitemid 46986233)
8. Viread (Tenofovir Disoproxil Fumarate) [package insert]. Gilead Sciences Foster City, CA; 2007. Registration number: A40/20.2.8/0681.
9. Mulenga LB, Kruse G, Lakhi S, Cantrell RA, Reid SE, Zulu I, et al. Baseline renal insufficiency and risk of death among HIV-infected adults on antiretroviral therapy in Lusaka, Zambia. AIDS 2008;22:1821-1827.
10. Fabian J, Naicker S. HIV and kidney disease in sub-Saharan Africa. Nat Rev Nephrol 2009;5:591-598.
11. Bihl G. HIV-related renal disease: a clinical and practical approach in the South African context. SAMJ 2003:11-14. (Pubitemid 36411205)
12. Franceschini N, Napravnik S, Eron J, Szczech LA, Finn WF. Incidence and etiology of acute renal failure among ambulatory HIV-infected patients. Kidney Int 2005;67:1526-1531. (Pubitemid 40463131)
13. National Department of Health, Republic of South Africa. The South African Antiretroviral Treatment Guidelines 2010. http://www.doh.gov. za/docs/factsheets/guidelines/art.pdf. [Assessed 20 October 2010]
14. Franey C, Knott D, Barnighausen T, Dedicoat M, Adam A, Lessells RJ, et al. Renal impairment in a rural African antiretroviral programme. MBMC Infect Dis 2009;9:143-147.
15. Nelson MR, Katlama C, Montaner JS, Cooper DA, Gazzard B, Clotet B, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 2007;21:1273-1281. (Pubitemid 46883481)
16. Gallant JE, Winston JA, DeJesus E, Pozniak AL, Chen SS, Cheng AK, et al. The 3-year renal safety of a tenofovir disoproxil fumarate vs a thymidine analogue-containing regimen in antiretroviral-naive patients. AIDS 2008;22:2155-2163.
17. Parish MA, Gallant JE, Moore R. Changes in renal function in patients treated with tenofovir DF vs nucleoside reverse transcriptase inhibitors. In: Proceedings of the Eleventh Conference on Retroviruses and Opportunistic Infections, San Francisco, CA; 2004. Abstract no. 751.
18. Crane H, Harrington R, Van Rompaey S, Kitahata M. Didanosine and lower baseline body weight are associated with declining renal function among patients receiving tenofovir. In: Proceedings of the Thirteenth Conference on Retroviruses and Opportunistic Infections, Denver; 2006. Abstract no. 780.
19. Thompson M, Haubrich R, Margolis D, Schneider S, Schooley R, Pappa KJ, et al. Differences in calculated glomerular filtration rates in efavirenz-or tenofovir-treated adults in ESS40006. In: Proceedings of the Thirteenth Conference on Retroviruses and Opportunistic Infections, Denver; 2006. Abstract no. 777.
20. Guest J, Rimland D, Patterson B, Desilva K. Tenofovir-induced nephrotoxicity in the first year of therapy. In: Proceedings of the Thirteenth Conference on Retroviruses and Opportunistic Infections, Denver; 2006. Abstract no. 778.
21. Heffelfinger J, Hanson DL, Voetsch AC, McNaghten AD, Sullivan PS. Renal impairment associated with the use of tenofovir. In: Proceedings of the Thirteenth Conference on Retroviruses and Opportunistic Infections, Denver; 2006. Abstract no. 778.
22. Gallant JE, Moore RD. Renal function with use of a tenofovircontaining initial antiretroviral regimen. AIDS 2009;24:1971-1975.
23. Sanusi AA, Akinsola A, Ajayi AA. Creatinine clearance estimation from serum creatinine values: evaluation and comparison of five prediction formulae in Nigerian patients. Afr J Med Med Sci 2000;29:7-11.
24. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of Tenofovir Disoproxil Fumarate in HIV-infected patients. Clin Infect Dis 2010;51:496-505.
25. Fairall LR, Bachmann MO, Louwagie GM, van Vuuren C, Chikobvu P, Steyn D, et al. Effectiveness of antiretroviral treatment in a South African program: a cohort study. Arch Intern Med 2008;168:86-93.
26. Fox MP, Brennan AB, Maskew M, MacPhail P, Sanne I. Using vital registration data to update mortality among patients lost to follow-up from ART programmes: evidence from the Themba Lethu Clinic, South Africa. TMIH 2010;15:405-413.
27. Boulle A, Van Cutsem G, Hilderbrand K, Carol C, Musaed A, Shaheed M, et al. Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS 2010;24:563-572.
28. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
29. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1-S266.
30. Naicker S. Challenges for nephrology practice is sub-Saharan Africa. Nephrol Dialysis Transplant 2010;25:649-650.
31. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000;11:550-560. (Pubitemid 30660034)
32. Hernán MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000;11:561-570. (Pubitemid 30660035)
33. Cole SR, Hernán MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol 2008;168:656-664.
34. Karras A, Lafaurie M, Furco A, Bourgarit A, Droz D, Sereni D, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome and nephrogenic diabetes insipidus. Clin Infect Dis 2003;36:1070-1073. (Pubitemid 36513295)
35. Padilla S, Gutierrez F, Masia M, Canovas V, Orozco C. Low frequency of renal function impairment during one-year of therapy with tenofovir-containing regimens in the real-world: a case-control study. AIDS Patient Care STDS 2005;19:421-424. (Pubitemid 41105521)
36. Jones R, Stebbing J, Nelson M, Moyle G, Bower M, Sundhiya M, et al. Renal dysfunction with tenofovir disoproxil fumaratecontaining highly active antiretroviral therapy regimes is not observed more frequently: a cohort and case-control study. JAIDS 2004;37:1489-1495. (Pubitemid 39602339)
37. Harris M, Joy R, Zalunardo N, Werb R, Yip B, Hogg R, Montaner J. Predictors of creatinine (Cr) increase and drug discontinuation in patients receiving tenofovir DF (TDF). In: Proceedings of the 8th International Congress on Drug Therapy in HIV Infection, Glasgow, Scotland; 2006. Abstract no. PL13.2.
38. Lucas GM, Lau B, Atta MG, Fine DM, Keruly J, Moore RD. Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races. J Infect Dis 2008;197:1548-1557. (Pubitemid 351706485)
39. Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010;329:841-845.
40. Herlitz LC, Mohan S, Stokes MB, et al. Tenofovir nephrotoxicity: acute tubularnecrosis with distinctiveclinical, pathological, and mitochondrial abnormalities. Kidney Int 2010;78:1171-1177.
41. Izzedine H, Hulot JS, Villard E, et al. Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis 2006;194:1481-1491. (Pubitemid 44851889)
42. Clumeck N, Pozniak A, Raffi F, EACS Executive Committee. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med 2008;9:65-71. (Pubitemid 351228129)
43. Norris KC, Greene T, Kopple J, Lea J, Lewis J, Lipkowitz M, et al. Baseline predictors of renal disease progression in the African American study of hypertension and kidney disease. J Am Soc Nephrol 2006;17:2928-2936. (Pubitemid 44484684)